CareDx (CDNA) said Wednesday it completed its previously announced acquisition of Naveris.
Transaction terms were disclosed when the deal was announced in April.
Naveris, a maker of blood-based tests for viral-mediated cancers, will be included in CareDx's consolidated financial results beginning in Q3.